Nabriva Therapeutics: Surges as pneumonia drug meets main goal in China study

Nabriva Therapeutics

26/05/2021 11:19

** Shares of the drugmaker  NBRV.O  soar ~66% premarket to
$2.45; set to open at highest in three months
    ** Co and Chinese partner Sinovant Sciences said their drug
lefamulin met the main goal in treating Chinese adults with
community acquired bacterial pneumonia in a late-stage study 
    ** Sinovant expects to submit marketing application for
lefamulin to China's regulatory body - National Medical Products
Administration, as soon as possible
    ** Shares set for their best session ever
    ** Stock down 39% YTD, as of last close

 (Reporting by Susan Mathew in Bengaluru;)
 ((susan.mathew@thomsonreuters.com; +91-80-6287-2704;))